source
- Novartis' $12B Avidity deal falters as DM1 therapy misses Phase 3 endpointNovartis' recent acquisition of Avidity Biosciences was intended to bring a novel therapy for Myotonic dystrophy type 1 (DM1) into its portfolio. The drug, del-desiran, an antibody-oligonucleotide…
- Roche inks $1 billion deal with Dualitas to screen 300,000 bispecific combos for immunology and inflammationRoche has agreed to pay Dualitas Therapeutics an upfront $36.5 million as part of a broader agreement that could be worth up to $1 billion. The collaboration will use Dualitas’s DualScreen platfor…